FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma

Season 5 Episode 4  ·  May 03, 2021, 08:12 PM

Headliner
Share
Subscribe

Dr. Abramson discusses the significance of the FDA approval of liso-cel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.

Share
Subscribe
Next
FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air